Kesimpta

Kesimpta outperforms Aubagio among ethnically diverse groups

Kesimpta (ofatumumab) is more effective than Aubagio (teriflunomide) among people with multiple sclerosis (MS) from ethnically diverse groups, including Black and African American, Hispanic and Latino, and Asian individuals, according to an analysis of pooled clinical trial data. ā€œDetermining whether there are differences in how people respond…

Researchers analyze switching to Kesimpta from oral therapies

People with relapsing multiple sclerosis (MS) who experienced disease activity while on oral therapies had less disease activity after switching to Kesimpta (ofatumumab), according to an analysis of data from the Phase 3 ARTIOS clinical trial. The patients previously were on Gilenya (fingolimod), or fumarate-based therapies such…

Mayzent and Kesimpta Gaining Ground as MS Treatments in Canada

Novartisā€™ Mayzent (siponimod) and Kesimpta (ofatumumab) are gaining ground among multiple sclerosisĀ (MS) therapies in Canada, according to the latest Spherix Global Insightsā€™ report. ā€œFollowing an eventful 2021 that included the launch of two new brands ā€” Novartisā€™ Kesimpta and BMS’ Zeposia ā€” and generic versions of Biogenā€™s…

Kesimpta Now Reimbursable for Patients in 2 Canadian Provinces

Kesimpta (ofatumumab) is now accessible to eligible Canadians with relapsing-remitting multiple sclerosis (RRMS) through public drug plans in Ontario and Quebec. The treatment has been included as an exceptional medication under both the Ontario Drug Benefit Exceptional Access Program and the RĆ©gie de lā€™assurance maladie du QuĆ©bec. This…

Ublituximab as Relapsing MS Therapy Under FDA Review

The U.S. Food and Drug Administration (FDA) has agreed to review TG Therapeuticsā€™ application seeking the approval of ublituximab as a treatment for people with relapsing forms ofĀ multiple sclerosis. An FDAā€™s decision is expected on or before Sept. 28. The agency is not currently planning to hold an…

Report: Tecfidera, Aubagio Preferred RRMS Treatments in Canada

Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of Spherixā€™sĀ RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS…

Ocrevus Still Top Therapy for Progressive MS Forms, Report Finds

Ocrevus (ocrelizumab) continues to be the most commonly prescribed therapy for progressive forms of multiple sclerosis (MS), including primary progressive MS (PPMS) and secondary progressive MS (SPMS), according to an analysis from the market intelligence firm Spherix Global Insights. However, other therapies are “gaining traction” among…

Anti-CD20 Therapies Show Similar Safety, Efficacy in RRMS

Anti-CD20 antibody therapies that target B-cells are highly effective for reducing the risk of relapses in people with relapsing-remitting multiple sclerosis (RRMS), a new analysis confirms. The analysis did not find any significant differences in efficacy or safety among the anti-CD20 therapies currently approved to treat RRMS, though…

Kesimpta for RRMS Now Available in Scotland at Low or No Cost

Adults in Scotland with active relapsing-remitting multiple sclerosis (RRMS) will now have access at low or no cost to Kesimpta (ofatumumab), the first self-administered, at-home B-cell-targeting therapy for people with the neurodegenerative disease. The Scottish Medicines Consortium (SMC) recommended that the Novartis therapy be available through the…

Long-term Kesimpta Use Not Seen in Trial to Depress Antibody Levels

Long-term use ofĀ Kesimpta (ofatumumab) among people with multiple sclerosis (MS) did not substantially lower their antibody levels, allowing them to retain an ability to fight infections, new data from a Phase 3 clinical trial indicate. “These long-term results continue to support Kesimpta as a high-efficacy, first-choice treatment with…

Kesimpta Approved in UK as At-home Relapsing MS Therapy

Kesimpta (ofatumumab) has been approved in the U.K. as the first self-administered, at-home, B-cell-targeting therapy for people with relapsing forms of multiple sclerosis (MS) and active disease. More specifically, the approval includes patients with eitherĀ clinically isolated syndrome,Ā relapsing-remitting MSĀ (RRMS), or active secondary progressive MSĀ (SPMS), who have…